Patient Portal

Nancy Lee Bartlett, MD

Professor, Medicine
Division of Oncology
Koman Chair in Medical Oncology

Specialty Areas

Medical Oncology
Oncology
Hematologic Malignancies
Lymphoma

Board Certifications

Internal Medicine
Oncology

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

Non-Hodgkin's and Hodgkin's lymphoma, chronic lymphocytic leukemia, hematologic malignancies

  • Location(s)
  • Education
  • Publication & Research

Location(s)

Location(s)

Center for Advanced Medicine
Siteman Cancer Center

4921 Parkview Place
St. Louis, MO 63110

Suite: B
Floor: 7
Office Phone: 314-747-1171
Fax: 314-747-5123

Education

Education

Fellowship: Medical Oncology, Stanford University, California 1993
Chief Residency: Medicine, University of California, San Francisco, California 1990
Residency: Medicine, University of California, San Francisco, California 1989
Medical Degree: Washington University School of Medicine, St. Louis, Missouri 1986
M.S.: Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 1979
B.A.: Chemical Engineering, Stanford University, California 1978

Publication & Research

Publication & Research

Reply to T.M. Weis et al.
Bartlett NL, Wilson WH, Leonard JP
J Clin Oncol. 2019 Sep 18; JCO1901617. doi: 10.1200/JCO.19.01617.

PMID:
    31532721
    [PubMed - as supplied by publisher]
Related citations


<b>Five-Year Follow-up of SWOG S0816: Limitations and Values of a PET-Adapted Approach for Stage III/IV Hodgkin Lymphoma</b>.
Stephens DM, Li H, Schöder H, Straus DJ, Moskowitz CH, Leblanc M, Rimsza LM, Bartlett NL, Evens AM, LaCasce AS, Barr PM, Knopp MV, Hsi E, Leonard JP, Kahl B, Smith SM, Friedberg JW
Blood. 2019 Jul 22; pii: blood.2019000719. doi: 10.1182/blood.2019000719.

PMID:
    31331918
    [PubMed - as supplied by publisher]
Related citations


Fifty Shades of GATA2 Mutation: A Case of Plasmablastic Lymphoma, Nontuberculous Mycobacterial Infection, and Myelodysplastic Syndrome.
Fakhri B, Cashen AF, Duncavage EJ, Watkins MP, Wartman LD, Bartlett NL
Clin Lymphoma Myeloma Leuk. 2019 Sep; 19(9)e532-e535. doi: 10.1016/j.clml.2019.05.015.

PMID:
    31279773
    [PubMed - in process]
Related citations


NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019.
Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Bartlett NL, Caimi PF, Chang JE, Chavez JC, Christian B, Fayad LE, Glenn MJ, Habermann TM, Lee Harris N, Hernandez-Ilizaliturri F, Kaminski MS, Kelsey CR, Khan N, Krivacic S, LaCasce AS, Mehta A, Nademanee A, Rabinovitch R, Reddy N, Reid E, Roberts KB, Smith SD, Snyder ED, Swinnen LJ, Vose JM, Dwyer MA, Sundar H
J Natl Compr Canc Netw. 2019 Jun 1; 17(6)650-661. doi: 10.6004/jnccn.2019.0029.

PMID:
    31200358
    [PubMed - in process]
Related citations


Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance).
Blum KA, Polley MY, Jung SH, Dockter TJ, Anderson S, Hsi ED, Wagner-Johnston N, Christian B, Atkins J, Cheson BD, Leonard JP, Bartlett NL
Cancer. 2019 Oct 1; 125(19)3378-3389. doi: 10.1002/cncr.32289.

PMID:
    31174236
    [PubMed - in process]
Related citations


Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.
Tilly H, Morschhauser F, Bartlett NL, Mehta A, Salles G, Haioun C, Munoz J, Chen AI, Kolibaba K, Lu D, Yan M, Penuel E, Hirata J, Lee C, Sharman JP
Lancet Oncol. 2019 Jul; 20(7)998-1010. doi: 10.1016/S1470-2045(19)30091-9.

PMID:
    31101489
    [PubMed - in process]
Related citations


Chemotherapy-Induced First Bite Syndrome: A Case Report in a Patient With Hodgkin Lymphoma.
Valenzuela CV, Bartlett NL, Bradley JP
Ear Nose Throat J. 2019 Jun; 98(5)E30-E31. doi: 10.1177/0145561319840534.

PMID:
    30961378
    [PubMed - in process]
Related citations


Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.
Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, Polley MC, Pitcher BN, Cheson BD, Kahl BS, Friedberg JW, Staudt LM, Wagner-Johnston ND, Blum KA, Abramson JS, Reddy NM, Winter JN, Chang JE, Gopal AK, Chadburn A, Mathew S, Fisher RI, Richards KL, Schöder H, Zelenetz AD, Leonard JP
J Clin Oncol. 2019 Jul 20; 37(21)1790-1799. doi: 10.1200/JCO.18.01994.

PMID:
    30939090
    [PubMed - in process]
Related citations


Progressive multifocal leukoencephalopathy treated with nivolumab.
Hoang E, Bartlett NL, Goyal MS, Schmidt RE, Clifford DB
J Neurovirol. 2019 Apr; 25(2)284-287. doi: 10.1007/s13365-019-00738-x.

PMID:
    30864100
    [PubMed - in process]
Related citations


Parameters for Validating a Hospital Pneumatic Tube System.
Farnsworth CW, Webber DM, Krekeler JA, Budelier MM, Bartlett NL, Gronowski AM
Clin Chem. 2019 May; 65(5)694-702. doi: 10.1373/clinchem.2018.301408.

PMID:
    30808643
    [PubMed - in process]
Related citations


To the Editor, A multicenter, open-label, early access treatment protocol for ibrutinib in patients with relapsed or refractory mantle cell lymphoma.
Martin P, Goy A, Ramchandren R, Ferrante L, Londhe A, McGowan T, Bartlett NL
J Oncol Pharm Pract. 2019 Jun; 25(4)1027-1030. doi: 10.1177/1078155219831435.

PMID:
    30786822
    [PubMed - in process]
Related citations


Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance).
Rosenbaum CA, Jung SH, Pitcher B, Bartlett NL, Smith SM, Hsi E, Wagner-Johnston N, Thomas SP, Leonard JP, Cheson BD
Br J Haematol. 2019 Apr; 185(1)53-64. doi: 10.1111/bjh.15768.

PMID:
    30723894
    [PubMed - in process]
Related citations


Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.
Hsi ED, Li H, Nixon AB, Schöder H, Bartlett NL, LeBlanc M, Smith S, Kahl BS, Leonard JP, Evens AM, Scott DW, Rimsza LM, Friedberg JW
Blood. 2019 Apr 18; 133(16)1762-1765. doi: 10.1182/blood-2018-08-870915.

PMID:
    30723079
    [PubMed - in process]
Related citations


A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.
Martin P, Bartlett NL, Blum KA, Park S, Maddocks K, Ruan J, Ridling L, Dittus C, Chen Z, Huang X, Inghirami G, DiLiberto M, Chen-Kiang S, Leonard JP
Blood. 2019 Mar 14; 133(11)1201-1204. doi: 10.1182/blood-2018-11-886457.

PMID:
    30692121
    [PubMed - in process]
Related citations


Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma.
Ramchandren R, Advani RH, Ansell SM, Bartlett NL, Chen R, Connors JM, Feldman T, Forero-Torres A, Friedberg JW, Gopal AK, Gordon LI, Kuruvilla J, Savage KJ, Younes A, Engley G, Manley TJ, Fenton K, Straus DJ
Clin Cancer Res. 2019 Mar 15; 25(6)1718-1726. doi: 10.1158/1078-0432.CCR-18-2435.

PMID:
    30617130
    [PubMed - in process]
Related citations


The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials.
Lansigan F, Barak I, Pitcher B, Jung SH, Cheson BD, Czuczman M, Martin P, Hsi E, Schöder H, Smith S, Bartlett NL, Leonard JP, Blum KA
Cancer Med. 2019 Jan; 8(1)165-173. doi: 10.1002/cam4.1918.

PMID:
    30575311
    [PubMed - in process]
Related citations


Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L, ECHELON-2 Study Group.
Lancet. 2019 Jan 19; 393(10168)229-240. doi: 10.1016/S0140-6736(18)32984-2.

PMID:
    30522922
    [PubMed - indexed for MEDLINE]
Related citations


Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, Lin Y, Braunschweig I, Hill BT, Timmerman JM, Deol A, Reagan PM, Stiff P, Flinn IW, Farooq U, Goy A, McSweeney PA, Munoz J, Siddiqi T, Chavez JC, Herrera AF, Bartlett NL, Wiezorek JS, Navale L, Xue A, Jiang Y, Bot A, Rossi JM, Kim JJ, Go WY, Neelapu SS
Lancet Oncol. 2019 Jan; 20(1)31-42. doi: 10.1016/S1470-2045(18)30864-7.

PMID:
    30518502
    [PubMed - in process]
Related citations


Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, Parekh S, Lacasce A, Hayslip JW, Jagadeesh D, Nagpal S, Lechowicz MJ, Gaur R, Lucas A, Melani C, Roschewski M, Steinberg SM, Jaffe ES, Kahl B, Friedberg JW, Little RF, Bartlett NL, Wilson WH
Lancet Haematol. 2018 Dec; 5(12)e609-e617. doi: 10.1016/S2352-3026(18)30177-7.

PMID:
    30501868
    [PubMed - indexed for MEDLINE]
Related citations


Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.
Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Coutre S, Hurria A, Brown JR, Lozanski G, Blachly JS, Ozer HG, Major-Elechi B, Fruth B, Nattam S, Larson RA, Erba H, Litzow M, Owen C, Kuzma C, Abramson JS, Little RF, Smith SE, Stone RM, Mandrekar SJ, Byrd JC
N Engl J Med. 2018 Dec 27; 379(26)2517-2528. doi: 10.1056/NEJMoa1812836.

PMID:
    30501481
    [PubMed - indexed for MEDLINE]
Related citations